AIMS/HYPOTHESIS: Increased extracellular matrix (ECM) collagen is a characteristic of muscle insulin resistance. Matrix metalloproteinase (MMP) 9 is a primary enzyme that degrades collagen IV (ColIV). As a component of the basement membrane, ColIV plays a key role in ECM remodelling. We tested the hypotheses that genetic deletion of MMP9 in mice increases muscle ColIV, induces insulin resistance in lean mice and worsens diet-induced muscle insulin resistance. METHODS: Wild-type (Mmp9(+/+)) and Mmp9-null (Mmp9(-/-)) mice were chow or high-fat (HF) fed for 16 weeks. Insulin action was measured by the hyperinsulinaemic-euglycaemic clamp in conscious weight-matched surgically catheterised mice. RESULTS: Mmp9(-/-) and HF feeding independently increased muscle ColIV. ColIV in HF-fed Mmp9(-/-) mice was further increased. Mmp9(-/-) did not affect fasting insulin or glucose in chow- or HF-fed mice. The glucose infusion rate (GIR), endogenous glucose appearance (EndoRa) and glucose disappearance (Rd) rates, and a muscle glucose metabolic index (Rg), were the same in chow-fed Mmp9(+/+) and Mmp9(-/-) mice. In contrast, HF-fed Mmp9(-/-) mice had decreased GIR, insulin-stimulated increase in Rd and muscle Rg. Insulin-stimulated suppression of EndoRa, however, remained the same in HF-fed Mmp9(-/-) and Mmp9(+/+) mice. Decreased muscle Rg in HF-fed Mmp9(-/-) was associated with decreased muscle capillaries. CONCLUSIONS/ INTERPRETATION: Despite increased muscle ColIV, genetic deletion of MMP9 does not induce insulin resistance in lean mice. In contrast, this deletion results in a more profound state of insulin resistance, specifically in the skeletal muscle of HF-fed mice. These results highlight the importance of ECM remodelling in determining muscle insulin resistance in the presence of HF diet.
AIMS/HYPOTHESIS: Increased extracellular matrix (ECM) collagen is a characteristic of muscle insulin resistance. Matrix metalloproteinase (MMP) 9 is a primary enzyme that degrades collagen IV (ColIV). As a component of the basement membrane, ColIV plays a key role in ECM remodelling. We tested the hypotheses that genetic deletion of MMP9 in mice increases muscle ColIV, induces insulin resistance in lean mice and worsens diet-induced muscle insulin resistance. METHODS: Wild-type (Mmp9(+/+)) and Mmp9-null (Mmp9(-/-)) mice were chow or high-fat (HF) fed for 16 weeks. Insulin action was measured by the hyperinsulinaemic-euglycaemic clamp in conscious weight-matched surgically catheterised mice. RESULTS:Mmp9(-/-) and HF feeding independently increased muscle ColIV. ColIV in HF-fed Mmp9(-/-) mice was further increased. Mmp9(-/-) did not affect fasting insulin or glucose in chow- or HF-fed mice. The glucose infusion rate (GIR), endogenous glucose appearance (EndoRa) and glucose disappearance (Rd) rates, and a muscle glucose metabolic index (Rg), were the same in chow-fed Mmp9(+/+) and Mmp9(-/-) mice. In contrast, HF-fed Mmp9(-/-) mice had decreased GIR, insulin-stimulated increase in Rd and muscle Rg. Insulin-stimulated suppression of EndoRa, however, remained the same in HF-fed Mmp9(-/-) and Mmp9(+/+) mice. Decreased muscle Rg in HF-fed Mmp9(-/-) was associated with decreased muscle capillaries. CONCLUSIONS/ INTERPRETATION: Despite increased muscle ColIV, genetic deletion of MMP9 does not induce insulin resistance in lean mice. In contrast, this deletion results in a more profound state of insulin resistance, specifically in the skeletal muscle of HF-fed mice. These results highlight the importance of ECM remodelling in determining muscle insulin resistance in the presence of HF diet.
Authors: G Bergers; R Brekken; G McMahon; T H Vu; T Itoh; K Tamaki; K Tanzawa; P Thorpe; S Itohara; Z Werb; D Hanahan Journal: Nat Cell Biol Date: 2000-10 Impact factor: 28.824
Authors: J A Martignetti; A A Aqeel; W A Sewairi; C E Boumah; M Kambouris; S A Mayouf; K V Sheth; W A Eid; O Dowling; J Harris; M J Glucksman; S Bahabri; B F Meyer; R J Desnick Journal: Nat Genet Date: 2001-07 Impact factor: 38.330
Authors: Li Kang; Louise Lantier; Arion Kennedy; Jeffrey S Bonner; Wesley H Mayes; Deanna P Bracy; Louis H Bookbinder; Alyssa H Hasty; Curtis B Thompson; David H Wasserman Journal: Diabetes Date: 2013-01-24 Impact factor: 9.461
Authors: Annie Hasib; Chandani K Hennayake; Deanna P Bracy; Aimée R Bugler-Lamb; Louise Lantier; Faisel Khan; Michael L J Ashford; Rory J McCrimmon; David H Wasserman; Li Kang Journal: Am J Physiol Endocrinol Metab Date: 2019-09-24 Impact factor: 4.310
Authors: K M Fanning; B Pfisterer; A T Davis; T D Presley; I M Williams; D H Wasserman; J M Cline; K Kavanagh Journal: Am J Physiol Regul Integr Comp Physiol Date: 2017-07-12 Impact factor: 3.619
Authors: Ian M Williams; Yolanda F Otero; Deanna P Bracy; David H Wasserman; Italo Biaggioni; Amy C Arnold Journal: Hypertension Date: 2016-03-14 Impact factor: 10.190
Authors: Justin Loloi; Amanda J Miller; Sarah S Bingaman; Yuval Silberman; Amy C Arnold Journal: Am J Physiol Endocrinol Metab Date: 2018-10-09 Impact factor: 4.310
Authors: Eric D Buras; Kimber Converso-Baran; Carol S Davis; Takeshi Akama; Fumihito Hikage; Daniel E Michele; Susan V Brooks; Tae-Hwa Chun Journal: Diabetes Date: 2018-10-25 Impact factor: 9.461
Authors: Artur Galimov; Angelika Hartung; Roman Trepp; Alexander Mader; Martin Flück; Axel Linke; Matthias Blüher; Emanuel Christ; Jan Krützfeldt Journal: J Mol Med (Berl) Date: 2015-07-23 Impact factor: 4.599